Efficacy and safety of double-dosage Clopidogrel in elderly patients with Clopidogrel resistance after percutaneous coronary intervention / 中华老年医学杂志
Chinese Journal of Geriatrics
; (12): 1065-1068, 2017.
Article
en Zh
| WPRIM
| ID: wpr-657994
Biblioteca responsable:
WPRO
ABSTRACT
Objective To evaluate the efficacy and safety of double-dosage Clopidogrel in elderly patients with Clopidogrel resistance after percutaneous coronary intervention(PCI).Methods The randomized control trials design was used in this study.108 senile ACS patients with Clopidogrel resistance(platelet inhibition rate＜ 30 ％) were randomized into control group(Clopidogrel 75 mg/d,n =54)and experimental group(Clopidogrel 150 mg/d,n=54).Blood platelet inhibition rate of ADP,major adverse cardiovascular events and main side effects were observed before and 7 d,30 d,90 d and 180 d after intervention.Results Compared with control group,the experimental group was associated with significantly increased platelet inhibition rate on 7 d (22.4 ± 4.5) ％ vs.(37.6 ± 4.5)％,30 d(22.6±4.3)％ vs.(38.8±4.7)％,90 d(22.7±4.6)％ vs.(38.5±4.5)％,and 180 d (23.7±4.3)％ vs.(38.9±4.6)％ after treatment(all P＜0.05).Furthermore,the incidence of main adverse cardiovascular events was also significantly lower in the experimental group(3.7％ vs.35.1％,x2 =15.133,P＜0.001).Meanwhile,the incidence of bleeding and dyspnea were higher in experimental group,but there was no significant difference between the two groups.Conclusions Compared with general dosage,double-dosage of Clopidogrel offers better curative effect and good safety in elderly ACS patients with Clopidogrel resistance after PCI.
Texto completo:
1
Base de datos:
WPRIM
Tipo de estudio:
Clinical_trials
Idioma:
Zh
Revista:
Chinese Journal of Geriatrics
Año:
2017
Tipo del documento:
Article